Patents by Inventor Robert A. Davey

Robert A. Davey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11884653
    Abstract: Ebola virus and Marburg virus are filoviruses and are responsible for outbreaks that cause up to 90% fatality, including the recent outbreak in West Africa that has resulted in over 11,000 deaths. The present disclosure generally relates to series novel arylnaphthalene compounds, having a formula (I) or a pharmaceutically acceptable salt thereof, as a vacuolar-ATPase inhibitor that are useful for the treatment for a broad spectrum of viral infections, including those infections caused by filoviruses. Pharmaceutical composition matters and methods of use are within the scope of this invention.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: January 30, 2024
    Assignees: Purdue Research Foundation, Trustees of Boston University
    Inventors: Vincent Jo Davisson, Aaron Raymond Lindstrom, Naoaki Fujii, Robert A. Davey
  • Patent number: 11571416
    Abstract: Described herein are pharmaceutical compositions capable of blocking entry of a virus into a host cell and containing one or more compounds of the general formula I or a pharmaceutically acceptable derivative thereof and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat viral infections.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: February 7, 2023
    Assignee: Kagoshima University
    Inventors: Robert A. Davey, Yasuteru Sakurai, Masanori Baba, Norikazu Sakakibara
  • Publication number: 20210230149
    Abstract: Ebola virus and Marburg virus are filoviruses and are responsible for outbreaks that cause up to 90% fatality, including the recent outbreak in West Africa that has resulted in over 11,000 deaths. The present disclosure generally relates to series novel arylnaphthalene compounds, having a formula (I) or a pharmaceutically acceptable salt thereof, as a vacuolar-ATPase inhibitor that are useful for the treatment for a broad spectrum of viral infections, including those infections caused by filoviruses. Pharmaceutical composition matters and methods of use are within the scope of this invention.
    Type: Application
    Filed: April 6, 2021
    Publication date: July 29, 2021
    Applicant: Purdue Research Foundation
    Inventors: Vincent Jo Davisson, Aaron Raymond Lindstrom, Naoaki Fujii, Robert A. Davey
  • Publication number: 20140378435
    Abstract: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Applicant: Board of Regents, University of Texas System
    Inventors: Robert A. Davey, Andrey A. Kolokoltsov, Mohammad F. Saeed
  • Patent number: 8889743
    Abstract: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: November 18, 2014
    Assignee: Board of Regents, University of Texas System
    Inventors: Robert A. Davey, Andrey A. Kolokoltsov, Mohammad F. Saeed
  • Publication number: 20110152344
    Abstract: The present invention discloses method to treat infections caused by filovirus. Such a method comprises blocking the PI3 kinase pathway or the calcium-associated pathway at the gene or protein level. Also disclosed herein are the compounds useful in the treatment of filoviral infection.
    Type: Application
    Filed: December 21, 2009
    Publication date: June 23, 2011
    Inventors: Robert A. Davey, Andrey A. Kolokoltsov, Mohammad F. Saeed
  • Patent number: 7807346
    Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: October 5, 2010
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Robert A Davey, Andrey Kolokoltsov
  • Patent number: 7623900
    Abstract: A method of navigating along a biological object with a lumen represented by a three-dimensional volume data set comprises generating a plurality of navigation segments connectable in a sequence, each segment having a start point within the lumen, a direction and a length. The navigation may be used for a camera in a virtual endoscopic examination, for example. The direction of each segment is determined by casting groups of rays outwards from the start point of the segment to the object wall, and calculating an average ray length for each group. The group having the largest average ray length is selected, and the axial direction of this group is used as the direction for the segment. The average ray lengths of the groups may be weighted using the direction of the previous segments to bias the navigation generally forward, or may be weighted using a view direction of the camera to allow a user to turn the camera into a chosen branch in the object.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: November 24, 2009
    Assignee: Toshiba Medical Visualization Systems Europe, Ltd.
    Inventors: Alan Graham, Andrew Smout, Robert A. Davey, Laurent Lessieux
  • Publication number: 20090214663
    Abstract: The present invention discloses method to coat nanoparticles with viral envelope containing specific proteins. The present invention also discloses that such viral envelope coated nanoparticles can be targeted to specific cells and cellular entry pathway, thereby permitting their use as vaccines, in targeted delivery of therapeutic products and in the study of virus adsorption, cell penetration and viral entry pathways.
    Type: Application
    Filed: March 26, 2009
    Publication date: August 27, 2009
    Inventors: Thomas B. Albrecht, Robert A. Davey
  • Publication number: 20080299085
    Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.
    Type: Application
    Filed: May 5, 2008
    Publication date: December 4, 2008
    Inventors: Robert A. Davey, Andrey Kolokoltsov
  • Patent number: 7368232
    Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins of the HIV Nef protein that would specifically associate with cell membranes to deliver the enzyme into viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.
    Type: Grant
    Filed: January 14, 2005
    Date of Patent: May 6, 2008
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Robert A. Davey, Andrey Kolokoltsov
  • Patent number: 7329486
    Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins that would deliver the enzyme into the viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.
    Type: Grant
    Filed: March 30, 2004
    Date of Patent: February 12, 2008
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Robert A. Davey, Andrey Kolokoltsov
  • Publication number: 20040191766
    Abstract: The present invention provides a rapid virus entry/binding detection assay. An enzyme such as luciferase was incorporated at the C-terminal end of viral envelope proteins that would deliver the enzyme into the viral particles upon viral assembly. Virus entry/binding can then be assayed by determining the enzymatic activities in infected cells. The assay allows high-throughput non-radioactive detection of virus entry within 30 minutes after virus-cell contact. This assay provides high signal to noise ratio and is useful for screening compounds that affect virus-cell binding and entry. The design also permits packaging of potential therapeutic proteins into functional virus particles and delivering them to specific cellular targets.
    Type: Application
    Filed: March 30, 2004
    Publication date: September 30, 2004
    Inventors: Robert A. Davey, Andrey Kolokoltsov
  • Publication number: 20020192799
    Abstract: The present invention provides collections of polypeptides, where each polypeptide includes a region Xaan, wherein n is from about 5 to about 21, and each Xaa is independently a random amino acid. Polynucleotides encoding the polypeptides, are also provided, as are methods for identifying a polypeptide within a collection that prevents cell death after exposure to a pathogen or a toxin, and methods for identifying a polypeptide within a collection that binds a pathogen, a toxin, a polypeptide, or a polynucleotide. The present invention also provides methods for crystallizing a polypeptide.
    Type: Application
    Filed: October 15, 2001
    Publication date: December 19, 2002
    Applicant: Board of Regents, The University of Texas System
    Inventors: Stanley J. Watowich, Scott C. Weaver, Robert A. Davey